Melissa J. Kasiewicz

483 total citations
18 papers, 365 citations indexed

About

Melissa J. Kasiewicz is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Melissa J. Kasiewicz has authored 18 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 13 papers in Oncology and 2 papers in Molecular Biology. Recurrent topics in Melissa J. Kasiewicz's work include Cancer Immunotherapy and Biomarkers (11 papers), Immune Cell Function and Interaction (8 papers) and Immunotherapy and Immune Responses (7 papers). Melissa J. Kasiewicz is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Immune Cell Function and Interaction (8 papers) and Immunotherapy and Immune Responses (7 papers). Melissa J. Kasiewicz collaborates with scholars based in United States, United Kingdom and India. Melissa J. Kasiewicz's co-authors include William L. Redmond, Stefanie N. Linch, Michael J. McNamara, Mohammad Farhad, Annah S. Rolig, Shelly Bambina, Benjamin Cottam, Zhaoyu Sun, Marka R. Crittenden and Talicia Savage and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Journal of Immunology and PLoS ONE.

In The Last Decade

Melissa J. Kasiewicz

17 papers receiving 356 citations

Peers

Countries citing papers authored by Melissa J. Kasiewicz

Since Specialization

Citations

This map shows the geographic impact of Melissa J. Kasiewicz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melissa J. Kasiewicz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melissa J. Kasiewicz more than expected).

Fields of papers citing papers by Melissa J. Kasiewicz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melissa J. Kasiewicz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melissa J. Kasiewicz. The network helps show where Melissa J. Kasiewicz may publish in the future.

Co-authorship network of co-authors of Melissa J. Kasiewicz

This figure shows the co-authorship network connecting the top 25 collaborators of Melissa J. Kasiewicz. A scholar is included among the top collaborators of Melissa J. Kasiewicz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melissa J. Kasiewicz. Melissa J. Kasiewicz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	The response to anti–PD-1 and anti–LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming 2025 ·Science Translational Medicine ·Annah S. Rolig, (unknown), (unknown), (unknown), Melissa J. Kasiewicz, (unknown), (unknown), William L. Miller, Yoshinobu Koguchi, Johanna K. Kaufmann, (unknown), (unknown), James Smothers, Matthew Adamow, (unknown), Ronglai Shen, Margaret K. Callahan, William L. Redmond	4
2	INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), (unknown), (unknown), Melissa J. Kasiewicz, (unknown), Annah S. Rolig, (unknown), Bryan R. Becklund, (unknown), Yoshinobu Koguchi, Brendan P. Eckelman, (unknown), William L. Redmond	4
3	Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA 2023 ·Frontiers in Immunology ·William L. Redmond, Melissa J. Kasiewicz, Emmanuel T. Akporiaye	1
4	Arginase Therapy Combines Effectively with Immune Checkpoint Blockade or Agonist Anti-OX40 Immunotherapy to Control Tumor Growth 2021 ·Cancer Immunology Research ·Mark Badeaux, Annah S. Rolig, (unknown), (unknown), Melissa J. Kasiewicz, (unknown), Jason F. Wiggins, Alexander Muir, Mark R. Sullivan, (unknown), Christopher Daige, Matthew G. Vander Heiden, Venkatesh Rajamanickam, James E. Wooldridge, William L. Redmond, Scott W. Rowlinson	15
5	Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity 2021 ·OncoImmunology ·(unknown), Annah S. Rolig, Stefanie N. Linch, (unknown), Melissa J. Kasiewicz, Zhaoyu Sun, Peter G. Traber, Harold Shlevin, William L. Redmond	34
6	NKTR-214 immunotherapy synergizes with radiotherapy to stimulate systemic CD8⁺ T cell responses capable of curing multi-focal cancer 2020 ·Journal for ImmunoTherapy of Cancer ·Joshua M. Walker, Annah S. Rolig, Deborah H. Charych, Ute Hoch, Melissa J. Kasiewicz, (unknown), Michael J. McNamara, (unknown), William L. Redmond	25
7	Abstract 1604: NKTR-214 synergizes with radiotherapy to drive tumor regression 2017 ·Cancer Research ·Michael J. McNamara, Melissa J. Kasiewicz, (unknown), Ute Hoch, Deborah H. Charych, William L. Redmond	1
8	Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice 2016 ·Proceedings of the National Academy of Sciences ·Stefanie N. Linch, Melissa J. Kasiewicz, Michael J. McNamara, (unknown), Mohammad Farhad, William L. Redmond	66
9	Interferon-γ Production by Peripheral Lymphocytes Predicts Survival of Tumor-Bearing Mice Receiving Dual PD-1/CTLA-4 Blockade 2016 ·Cancer Immunology Research ·Michael J. McNamara, (unknown), (unknown), Stefanie N. Linch, Melissa J. Kasiewicz, William L. Redmond	20
10	Galectin-3 inhibition using novel inhibitor GR-MD-02 improves survival and immune function while reducing tumor vasculature 2016 ·The Journal of Immunology ·Stefanie N. Linch, Melissa J. Kasiewicz, Michael J. McNamara, (unknown), Mohammad Farhad, Peter G. Traber, William L. Redmond	3
11	Galectin-3 inhibition using novel inhibitor GR-MD-02 improves survival and immune function while reducing tumor vasculature 2015 ·Journal for ImmunoTherapy of Cancer ·Stefanie N. Linch, Melissa J. Kasiewicz, Michael J. McNamara, (unknown), Mohammad Farhad, William L. Redmond	8
12	Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice 2015 ·Journal for ImmunoTherapy of Cancer ·Stefanie N. Linch, Melissa J. Kasiewicz, Michael J. McNamara, (unknown), Mohammad Farhad, William L. Redmond	0
13	Common gamma chain (γc) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8+ T cells 2014 ·Journal for ImmunoTherapy of Cancer ·Michael J. McNamara, Melissa J. Kasiewicz, Stefanie N. Linch, Christopher Dubay, William L. Redmond	9
14	Preparative immunotherapy with anti-OX40 and anti-CTLA4 improves the response to chemotherapy 2014 ·Journal for ImmunoTherapy of Cancer ·David J. Friedman, Kristina H. Young, Jason R. Baird, Benjamin Cottam, Talicia Savage, Pippa Newell, Melissa J. Kasiewicz, William L. Redmond, Brendan D. Curti, Todd S. Crocenzi, Michael J. Gough, Marka R. Crittenden	1
15	Common gamma chain (¿c) cytokines differentially potentiate TNFR family signaling in antigen-activated CD8 + T cells 2014 ·Journal for ImmunoTherapy of Cancer ·Michael J. McNamara, Melissa J. Kasiewicz, Stefanie N. Linch, Christopher Dubay, William L. Redmond	1
16	Combined Targeting of Costimulatory (OX40) and Coinhibitory (CTLA-4) Pathways Elicits Potent Effector T Cells Capable of Driving Robust Antitumor Immunity 2013 ·Cancer Immunology Research ·William L. Redmond, Stefanie N. Linch, Melissa J. Kasiewicz	126
17	The Peripheral Myeloid Expansion Driven by Murine Cancer Progression Is Reversed by Radiation Therapy of the Tumor 2013 ·PLoS ONE ·Marka R. Crittenden, Talicia Savage, Benjamin Cottam, Keith S. Bahjat, William L. Redmond, Shelly Bambina, Melissa J. Kasiewicz, Pippa Newell, Andrew M. Jackson, Michael J. Gough	39
18	Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity 2013 ·Journal for ImmunoTherapy of Cancer ·William L. Redmond, Stefanie N. Linch, Melissa J. Kasiewicz	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact